1. Home
  2. TSAT vs OCGN Comparison

TSAT vs OCGN Comparison

Compare TSAT & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$35.60

Market Cap

390.1M

Sector

Industrials

ML Signal

HOLD

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.97

Market Cap

387.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
OCGN
Founded
1969
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.1M
387.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
TSAT
OCGN
Price
$35.60
$1.97
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
111.6K
4.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.58
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.88
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.81
$0.52
52 Week High
$36.85
$1.96

Technical Indicators

Market Signals
Indicator
TSAT
OCGN
Relative Strength Index (RSI) 67.27 67.14
Support Level $28.22 $1.48
Resistance Level $36.81 N/A
Average True Range (ATR) 2.20 0.14
MACD 0.71 0.04
Stochastic Oscillator 95.28 92.74

Price Performance

Historical Comparison
TSAT
OCGN

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: